GRAIL collaborates with AstraZeneca to make companion diagnostic tests for early-stage cancer
vitanovski/iStock via Getty Images


Illumina (NASDAQ:ILMN) unit GRAIL on Thursday announced a collaboration with AstraZeneca (AZN) to make and sell companion diagnostic assays for use with AZN's therapies.
GRAIL, which focuses on technologies for early detection of cancer, said the collaboration will initially focus on developing companion diagnostic tests to identify patients with high-risk, early-stage cancers.

GRAIL and AZN are also planning to use GRAILâs technology to enable recruitment of patients with early-stage cancer for Astraâs clinical studies.
Across the projects within the collaboration, GRAIL will perform testing for patients enrolled in AZN's clinical trials.
ILMN stock +0.7% to $236.92 in morning trade, while U.S.-listed shares of AZN -0.7% to % $65.64.